SavedAdd your journal

Journals / İstanbul Üniversitesi Veteriner Fakültesi Dergisi / 2017 / Cilt: 43 - Sayı: 2

Modulating Liver Cholesterol Metabolism by 3-Iodothyronamine

Nasrin KAZEMIPOUR
Saeed NAZIFI
Neda ESKANDARZADE
Sareh HADIAN
Pages
92–97
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It appears that T1AM reduced serum LDL and cholesterol just like T3, in contrast, it decreased liver cholesterol biosynthesis contrary to THs

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, we attempt to find out whether chronic low dose 3-Iodothyronamine (an endogenous metabolite of thyroid hormone) administration could modulate liver de novo cholesterol synthesis, the same as thyroid hormones.
📊
Key Findings & Data:Eighteen male mice were divided randomly into treatment (n=10) and control (n=8) groups.
💡
Conclusion & Impact:It appears that T1AM reduced serum LDL and cholesterol just like T3, in contrast, it decreased liver cholesterol biosynthesis contrary to THs
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study, we attempt to find out whether chronic low dose 3-Iodothyronamine (an endogenous metabolite of thyroid hormone) administration could modulate liver de novo cholesterol synthesis, the same as thyroid hormones. Eighteen male mice were divided randomly into treatment (n=10) and control (n=8) groups. The experimental procedure was applied for 7 days during which test group received T1AM whereas the control group received dimethyl sulfoxide and normal saline. The liver was analyzed for HMG-CoA reductase concentration and hepatic lipase activity whiles cholesterol, LDL and HDL concentrations were measured in the blood serum. There was non-significant decrease in HMG-CoA reductase concentration (224±21.2 versus 187±32.5) in test group compared to control. Interestingly LDL and cholesterol concentrations exhibited significant decrease in test group versus the control. There was non-significant decrease in hepatic lipase activity (771±316 versus 645±317) in test group versus the control. It appears that T1AM reduced serum LDL and cholesterol just like T3, in contrast, it decreased liver cholesterol biosynthesis contrary to THs

🔖

Cite This Article

KAZEMIPOUR, N., NAZIFI, S., ESKANDARZADE, N., HADIAN, S. (2022). Modulating Liver Cholesterol Metabolism by 3-Iodothyronamine. İstanbul Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 43 - Sayı: 2, 92–97. https://ajindex.com/articles/555032

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Angelin, B., Rudling, M., 2010. Lipid lowering with thyroid hormone and thyromimetics. Current Opinion in Lipidology 21, 499-506.
  2. Bakker, O., Hudig, F., Meijssen, S., Wiersinga, W.M., 1998. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochemical and Biophysical Research Communications 240, 517-521.
  3. Beh, C.T., Cool, L., Phillips, J., Rine, J., 2001. Overlapping functions of the yeast oxysterol-binding protein homologues. Genetics 157, 1117-1140.
  4. Burtis, C.A., Ashwood, E.R., 1994. Tietz Textbook of Clinical Chemistry, 2nd (Ed). Philadelphia, W.B. Saunders Company, pp.443-449.
  5. Canaris, G.J., Manowitz, N.R., Mayor, G., Ridgway, C., 2000. The Colorado thyroid disease prevalence study. Archives of Internal Medicine 160, 526-534.
  6. Cumero, S., Fogolari, F., Domenis, R., Zucchi, R., Mavelli, I., Contessi, S., 2012. Mitochondrial F0F1 -ATP synthase is a molecular target of 3-iodothyronamine, an endogenous metabolite of thyroid hormone. British Journal of Pharmacology 166, 2331-2347.
  7. Gachon, F., Leuenberger, N., Claudel, T., Gos, P., Jouffe, C., Fleury Olela, F., de Mollerat du Jeu, X., Wahli, W., Schibler, U., 2011. Proline-and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor α (PPARα) activity. Proceedings of the National Academy of Sciences USA 108, 4794-4799.
  8. Gill, S., Chow, R., Brown, A.J., 2008. Sterol regulators of cholesterol homeostasis and beyond: the oxysterol hypothesis revisited and revised. Progress in Lipid Research 47, 391-404.
  9. Goldberg, I.J., Huang, L., Huggins, L.A., Yu, S., Nagareddy, P.R., Scanlan, T.S., Ehrenkranz, J.R., 2012. Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway. Endocrinology 153, 5143-5149.
  10. Istvan, E.S., Deisenhofer, J., 2001. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164.
  11. Karackattu, S.L., Trigatti, B., Krieger, M., 2006. Hepatic lipase deficiency delays atherosclerosis, myocardial infarction, and cardiac dysfunction and extends lifespan in SRBI/apolipoprotein E double knockout mice. Arteriosclerosis, Thrombosis, and Vascular Biology 26, 548-54.
  12. Kovanen, P.T., Nikkila, E.A., Miettinen, T.A., 1975. Regulation of cholesterol synthesis and storage in fat cells. The Journal of Lipid Research 16, 211-223.
  13. Kussi, T., Sacrinen, P., Nikkila, E.A., 1980. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein 2 in man. Athe